Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Integra LifeSciences (NASDAQ:IART) posted its quarterly earnings data on Tuesday. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12, Zacks reports. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the previous year, the business earned $0.89 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year.

Integra LifeSciences Trading Down 1.5 %

Shares of NASDAQ IART traded down $0.36 during midday trading on Thursday, reaching $23.24. 91,111 shares of the stock were exchanged, compared to its average volume of 597,128. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $41.17. The stock has a market capitalization of $1.79 billion, a P/E ratio of -259.30, a PEG ratio of 0.73 and a beta of 1.17. The company has a 50 day simple moving average of $23.74 and a 200 day simple moving average of $21.84. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Citigroup lifted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley began coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $23.00.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by company insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.